PredxBio Announces Strategic Leadership Transition and Focus on Spatial Multi-Omic Biomarkers
On December 8, 2025, PredxBio, an innovator in AI-driven spatial biomarkers and precision oncology, revealed significant leadership changes aimed at bolstering the company’s scientific and commercial growth. The Board of Directors has appointed Dr. S. Chakra Chennubhotla, a Co-Founder and the former Chief Operating Officer, as the new Chief Executive Officer.
This leadership shift comes as PredxBio seeks to expand its offerings in tissue-based spatial biomarkers, utilizing advanced spatial analytics and explainable AI technologies. These developments are designed to provide pharmaceutical partners with enhanced insights into the tumor microenvironment, ultimately leading to improved oncology drug development.
Chennubhotla stated, “Our team has built a solid foundation in scientific and technological advancement, and we are committed to collaborating with biopharma to deliver spatial biomarkers that are robust and applicable in real-world scenarios.”
The company plans to enhance its engagement with biopharma partners by deepening its multi-omic data capabilities and optimizing workflows for discovery and clinical trials. Dr. Stanley Marks, Chairman of the Board, expressed confidence in Dr. Chennubhotla’s leadership, noting his pivotal role in establishing the company’s scientific underpinnings and fostering strong partnerships.
Under Dr. Chennubhotla’s guidance, PredxBio aims to advance its proprietary spatial biomarker analytics and develop a scalable SaaS platform that integrates tissue-based biomarkers throughout the pharmaceutical value chain.
Additional members of PredxBio’s leadership team include Dr. Filippo Pullara, Chief Scientific Officer, who will oversee scientific strategy and multi-omic development; Dr. A. Burak Tosun, Chief Technology Officer, responsible for platform engineering; and Sambhav Dave, VP of Business Development, tasked with driving commercial partnerships.
About PredxBio:
PredxBio transforms tumor biopsy images into actionable predictive biomarkers through advanced spatial analytics and AI technologies. Their comprehensive platform enhances oncology drug discovery and clinical development, making complex tumor biology more accessible and interpretable. For further information, visit www.predxbio.com.
